{
 "disease": "testicular-cancer",
 "label": "Testicular cancer",
 "url": "https://usebiotransfer.org/disease/testicular-cancer/",
 "built": "2026-09-12",
 "facts_hash": {
  "answers": "a9ba6e43f4cf",
  "targets": "9cfc7db355e1"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-12",
  "trials": "2026-09-12"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "KIT",
   "ensembl": "ENSG00000157404",
   "n_drug_entries": 38,
   "n_distinct_drugs": 33,
   "drugs": {
    "AMUVATINIB": "PHASE_2",
    "AVAPRITINIB": "APPROVAL",
    "BRIQUILIMAB": "PHASE_2",
    "CATEQUENTINIB": "PHASE_3",
    "CEDIRANIB": "APPROVAL",
    "CM-082": "PHASE_2",
    "DASATINIB": "APPROVAL",
    "DOVITINIB": "PHASE_3",
    "ENMD-2076": "PHASE_2",
    "FAMITINIB": "PHASE_3",
    "FORETINIB": "PHASE_2",
    "IMATINIB": "APPROVAL",
    "MASITINIB": "APPROVAL",
    "MIDOSTAURIN": "APPROVAL",
    "MOTESANIB": "PHASE_3",
    "OSI-930": "PHASE_1",
    "PAZOPANIB": "APPROVAL",
    "PEXIDARTINIB": "APPROVAL",
    "QUIZARTINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RIPRETINIB": "APPROVAL",
    "SEMAXANIB": "PHASE_3",
    "SERALUTINIB": "PHASE_3",
    "SORAFENIB": "APPROVAL",
    "SU-014813": "PHASE_2",
    "SUNITINIB": "APPROVAL",
    "SUNITINIB MALATE": "APPROVAL",
    "TANDUTINIB": "PHASE_2",
    "TELATINIB": "PHASE_2",
    "TIVOZANIB": "APPROVAL",
    "VATALANIB": "PHASE_3",
    "XL-820": "PHASE_2",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "AVAPRITINIB",
    "CEDIRANIB",
    "DASATINIB",
    "IMATINIB",
    "MASITINIB",
    "MIDOSTAURIN",
    "PAZOPANIB",
    "PEXIDARTINIB",
    "QUIZARTINIB",
    "REGORAFENIB",
    "RIPRETINIB",
    "SORAFENIB",
    "SUNITINIB",
    "SUNITINIB MALATE",
    "TIVOZANIB"
   ],
   "n_approved": 15,
   "approved_for": {
    "AVAPRITINIB": [
     "gastrointestinal stromal tumor"
    ],
    "CEDIRANIB": [],
    "DASATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "acute lymphoblastic leukemia",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "lymphoid leukemia"
    ],
    "IMATINIB": [
     "chronic myelogenous leukemia, BCR-ABL1 positive",
     "myelodysplastic/myeloproliferative disease",
     "gastrointestinal stromal tumor",
     "dermatofibrosarcoma protuberans",
     "blast phase chronic myelogenous leukemia, BCR-ABL1 positive",
     "B-cell acute lymphoblastic leukemia",
     "hypereosinophilic syndrome"
    ],
    "MASITINIB": [],
    "MIDOSTAURIN": [
     "mast cell leukemia",
     "mastocytosis",
     "acute myeloid leukemia by FAB classification",
     "systemic mastocytosis",
     "acute myeloid leukemia"
    ],
    "PAZOPANIB": [
     "renal cell carcinoma",
     "soft tissue sarcoma",
     "sarcoma"
    ],
    "PEXIDARTINIB": [
     "tenosynovial giant cell tumor",
     "tenosynovial giant cell tumor, diffuse type"
    ],
    "QUIZARTINIB": [
     "acute myeloid leukemia by FAB classification"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "RIPRETINIB": [
     "gastrointestinal stromal tumor"
    ],
    "SORAFENIB": [
     "renal cell carcinoma",
     "hepatocellular carcinoma",
     "thyroid gland carcinoma"
    ],
    "SUNITINIB": [
     "gastrointestinal stromal tumor",
     "renal cell carcinoma",
     "neuroendocrine neoplasm"
    ],
    "SUNITINIB MALATE": [
     "renal cell carcinoma",
     "gastrointestinal stromal tumor",
     "neuroendocrine neoplasm"
    ],
    "TIVOZANIB": [
     "renal cell carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "KRAS",
   "ensembl": "ENSG00000133703",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "ADAGRASIB": "APPROVAL",
    "SALIRASIB": "PHASE_2",
    "SOTORASIB": "APPROVAL"
   },
   "approved": [
    "ADAGRASIB",
    "SOTORASIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ADAGRASIB": [
     "non-small cell lung carcinoma"
    ],
    "SOTORASIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MDM2",
   "ensembl": "ENSG00000135679",
   "n_drug_entries": 4,
   "n_distinct_drugs": 4,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "NANOG",
   "ensembl": "ENSG00000111704",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "POU5F1",
   "ensembl": "ENSG00000204531",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "SOX17",
   "ensembl": "ENSG00000164736",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "SOX2",
   "ensembl": "ENSG00000181449",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "CCND2",
   "ensembl": "ENSG00000118971",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "TERT",
   "ensembl": "ENSG00000164362",
   "n_drug_entries": 2,
   "n_distinct_drugs": 1,
   "drugs": {
    "IMETELSTAT": "APPROVAL"
   },
   "approved": [
    "IMETELSTAT"
   ],
   "n_approved": 1,
   "approved_for": {
    "IMETELSTAT": [
     "anemia",
     "myelodysplastic syndrome"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "XIST",
   "ensembl": "ENSG00000229807",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  }
 ],
 "trials": {
  "by_antigen": {
   "CLDN6": {
    "n": 6,
    "n_observational": 0,
    "n_active": 4,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05410717",
      "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06276491",
      "title": "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06515613",
      "title": "A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04503278",
      "title": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06681870",
      "title": "A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2025-01-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06940804",
      "title": "A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm",
      "status": "WITHDRAWN",
      "last_update": "2025-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 3,
     "n_observational": 0,
     "n_active": 2,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT05410717",
       "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04503278",
       "title": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06940804",
       "title": "A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm",
       "status": "WITHDRAWN",
       "last_update": "2025-07-02",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CLDN6",
     "claudin 6",
     "claudin-6",
     "BNT211"
    ]
   },
   "PD-1": {
    "n": 9,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05410717",
      "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041503",
      "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02499952",
      "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
      "status": "TERMINATED",
      "last_update": "2022-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02857426",
      "title": "A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)",
      "status": "COMPLETED",
      "last_update": "2021-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571360",
      "title": "CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients",
      "status": "UNKNOWN",
      "last_update": "2020-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238883",
      "title": "A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05410717",
       "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab"
    ]
   },
   "PD-L1": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05410717",
      "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06041503",
      "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)",
      "status": "RECRUITING",
      "last_update": "2026-08-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02499952",
      "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
      "status": "TERMINATED",
      "last_update": "2022-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03081923",
      "title": "Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors",
      "status": "TERMINATED",
      "last_update": "2021-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03403777",
      "title": "Avelumab in Refractory Testicular Germ Cell Cancer.",
      "status": "COMPLETED",
      "last_update": "2019-03-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03571360",
      "title": "CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients",
      "status": "UNKNOWN",
      "last_update": "2020-06-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05410717",
       "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PD-L1",
     "durvalumab",
     "avelumab"
    ]
   },
   "CD30": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01851200",
      "title": "Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2018-02-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02689219",
      "title": "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors",
      "status": "TERMINATED",
      "last_update": "2019-12-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CD30",
     "brentuximab"
    ]
   },
   "CTLA-4": {
    "n": 9,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05410717",
      "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060372",
      "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer",
      "status": "COMPLETED",
      "last_update": "2013-03-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00089076",
      "title": "MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-05-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00140855",
      "title": "A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma",
      "status": "TERMINATED",
      "last_update": "2022-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01769222",
      "title": "Ipilimumab and Local Radiation for Selected Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "status": "COMPLETED",
      "last_update": "2022-12-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03081923",
      "title": "Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors",
      "status": "TERMINATED",
      "last_update": "2021-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05410717",
       "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab",
     "tremelimumab"
    ]
   }
  },
  "by_drug": {
   "CEDIRANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00458731",
      "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",
      "status": "COMPLETED",
      "last_update": "2014-02-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DASATINIB": {
    "n": 5,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00608361",
      "title": "Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2015-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00788125",
      "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-07-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01609816",
      "title": "Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01643603",
      "title": "Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",
      "status": "TERMINATED",
      "last_update": "2020-12-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02883049",
      "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations",
      "status": "COMPLETED",
      "last_update": "2026-06-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IMATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00042952",
      "title": "Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer",
      "status": "TERMINATED",
      "last_update": "2013-01-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PAZOPANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01743482",
      "title": "Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors",
      "status": "COMPLETED",
      "last_update": "2021-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SORAFENIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00772694",
      "title": "Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy",
      "status": "UNKNOWN",
      "last_update": "2008-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00453310",
      "title": "Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment",
      "status": "COMPLETED",
      "last_update": "2015-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00890747",
      "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy",
      "status": "COMPLETED",
      "last_update": "2014-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SUNITINIB MALATE": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00453310",
      "title": "Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment",
      "status": "COMPLETED",
      "last_update": "2015-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00890747",
      "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy",
      "status": "COMPLETED",
      "last_update": "2014-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}